Authors
Latest:
Assessing the Durability and Toxicity of CAR T-Cell Therapy in DLBCLElise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Importance of Sequencing Immunotherapy in Breast CancerElizabeth A. Mittendorf, MD, PhD, discusses different data looking at sequencing therapies and why it is important in the breast cancer setting.<br />
Latest:
Life Expectancy Should be a Consideration When Treating Older Breast Cancer Patients, Expert SaysHyman Muss, MD, discusses special considerations that should be taken when treating older patients with HER2-positive or triple-negative breast cancer.
Latest:
The Utility of the Myriad myRisk Hereditary Cancer TestElizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.
Latest:
Early Efficacy With Mosunetuzumab Appears Promising for Follicular and Other LymphomasElizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.
Latest:
Discussing the Investigation of Polatuzumab Combination Therapy in DLBCLElizabeth Lihua Budde, MD, PhD, breaks down the design and baseline characteristics of the phase 3 POLARIX trial that led to the approval of polatuzumab in combination with R-CHP for certain patients with diffuse large B-cell lymphoma.
Latest:
The Role of Immunotherapy in the Future Treatment Landscape of SarcomaElizabeth Loggers, MD, PhD, medical oncologist, Seattle Cancer Care Alliance, discusses the role that she expects immunotherapy will play in the future treatment landscape of sarcoma.
Latest:
Current Research on Identifying Biomarkers in Breast CancerElizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable.
Latest:
Unmet Needs and Future Outlook in aRCC TreatmentThe panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.
Latest:
Using Methylation as a Predictor for Response in Ovarian CancerElizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.
Latest:
The Oncologist's Guide to Direct-to-Consumer Genetic TestingEllen T. Matloff, a certified genetic counselor and the president and CEO of MyGeneCounsel.com, gives advice to oncologists on navigating direct-to-consumer genetic testing.
Latest:
Osimertinib Established as Preferred EGFR TKI Treatment in EGFR-Mutated NSCLCIn an interview with Targeted Oncology during the 14th Annual New York Lung Cancers Symposium, Zofia Piotrowska, MD, MHS, discussed the role of osimertinib in treating patients with EGFR-mutant NSCLC and how it compares with other therapeutic options in that space.
Latest:
Optimal Patient Selection for Denosumab in Giant Cell Tumor of BoneEmanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone.
Latest:
Rationalizing the Use of Pembrolizumab/Bevacizumab in Women With Recurrent Ovarian CancerEmese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center explains the rationale for the a phase II study, which combined pembrolizumab with bevacizumab in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the SGO Annual Meeting.
Latest:
Personalizing Treatment of Early-Stage Breast CancerEmiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.
Latest:
Liquid Biopsy Analysis of FGFR3 and PIK3CA for Disease Surveillance in Bladder CancerEmil Christensen, PhD candidate, Aarhus University Hospital, Denmark, discusses a liquid biopsy analysis of <em>FGFR3</em> and <em>PIK3CA</em> hotspot mutations for disease surveillance in bladder cancer.
Latest:
Examining Standard Radiation Treatments for the Long-Term Management of HCCThe research around best radiation-based treatment options for patients with hepatocellular carcinoma are over 15 years old, but the standard of care for long-term management of the disease is still conventional chemoembolization, according to Emil I. Cohen, MD, assistant professor, Georgetown University Hospital.
Latest:
Atezolizumab Makes Inroads in Non–Small Cell Lung CancerSingle-agent atezolizumab (formerly MPDL3280A) had excellent clinical activity in both chemotherapy-naïve and previously treated patients with metastatic non–small cell lung cancer (NSCLC) in the phase II FIR study,
Latest:
Comparing Neoadjuvant Chemotherapy Versus Surgery in Ovarian Cancer CareEmma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses which patients with ovarian cancer are better candidates for neoadjuvant chemotherapy versus surgery.
Latest:
More Approaches Are Emerging in TP53-Mutated AMLAlthough the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.
Latest:
Targeted Advances in MelanomaUntil recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with DTIC and immunotherapy with HD IL-2 or interferon-α.
Latest:
Biliary Cancer: Current Management and Emerging Targeted TherapiesBiliary cancer includes gallbladder carcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma.
Latest:
Dr. Emmanuel S. Antonarakis on the Future of the AR-V7 Biomarker in Prostate CancerEmmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, on the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker.
